Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) EBIT (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed EBIT for 4 consecutive years, with -$53.8 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT fell 15.91% to -$53.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$213.8 million, a 32.26% decrease, with the full-year FY2024 number at -$201.1 million, down 17.38% from a year prior.
  • EBIT was -$53.8 million for Q3 2025 at Centessa Pharmaceuticals, up from -$54.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$30.8 million in Q1 2025 to a low of -$74.6 million in Q4 2024.
  • A 4-year average of -$48.3 million and a median of -$47.0 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: surged 31.27% in 2023, then tumbled 112.01% in 2024.
  • Centessa Pharmaceuticals' EBIT stood at -$41.6 million in 2022, then increased by 15.44% to -$35.2 million in 2023, then plummeted by 112.01% to -$74.6 million in 2024, then rose by 27.88% to -$53.8 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's EBIT are -$53.8 million (Q3 2025), -$54.7 million (Q2 2025), and -$30.8 million (Q1 2025).